206 related articles for article (PubMed ID: 17382725)
1. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience.
Spiess PE; Kassouf W; Brown GA; Kamat AM; Liu P; Gomez JA; Tu SM; Tannir NM; Pisters LL
J Urol; 2007 Apr; 177(4):1330-4; discussion 1334. PubMed ID: 17382725
[TBL] [Abstract][Full Text] [Related]
2. The role of retroperitoneal lymphadenectomy in mature teratoma of the testis.
Heidenreich A; Moul JW; McLeod DG; Mostofi FK; Engelmann UH
J Urol; 1997 Jan; 157(1):160-3. PubMed ID: 8976241
[TBL] [Abstract][Full Text] [Related]
3. Repeat retroperitoneal lymph node dissection for metastatic testis cancer.
Sexton WJ; Wood CG; Kim R; Pisters LL
J Urol; 2003 Apr; 169(4):1353-6. PubMed ID: 12629359
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
J Urol; 2009 Jun; 181(6):2526-32. PubMed ID: 19371895
[TBL] [Abstract][Full Text] [Related]
5. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
Williams SB; Steele GS; Richie JP
J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777
[TBL] [Abstract][Full Text] [Related]
6. Growing teratoma syndrome: experience of a single institution.
Maroto P; Tabernero JM; Villavicencio H; Mesía R; Marcuello E; Solé-Balcells FJ; Sola C; Mora J; Algaba F; Pérez C; León X; López López JJ
Eur Urol; 1997; 32(3):305-9. PubMed ID: 9358218
[TBL] [Abstract][Full Text] [Related]
7. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
Svatek RS; Spiess PE; Sundi D; Tu SM; Tannir NM; Brown GA; Kamat AM; Wood CG; Pisters LL
Cancer; 2009 Mar; 115(6):1310-7. PubMed ID: 19156903
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
10. Primary pure teratoma of the testis.
Simmonds PD; Lee AH; Theaker JM; Tung K; Smart CJ; Mead GM
J Urol; 1996 Mar; 155(3):939-42. PubMed ID: 8583612
[TBL] [Abstract][Full Text] [Related]
11. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience.
Evans JG; Spiess PE; Kamat AM; Wood CG; Hernandez M; Pettaway CA; Dinney CP; Pisters LL
J Urol; 2006 Oct; 176(4 Pt 1):1463-7. PubMed ID: 16952661
[TBL] [Abstract][Full Text] [Related]
12. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer.
Heidenreich A; Ohlmann C; Hegele A; Beyer J
Eur Urol; 2005 Jan; 47(1):64-71. PubMed ID: 15582251
[TBL] [Abstract][Full Text] [Related]
13. Growing teratoma syndrome: clinical and radiographic characteristics.
Lee DJ; Djaladat H; Tadros NN; Movassaghi M; Tejura T; Duddalwar V; Daneshmand S
Int J Urol; 2014 Sep; 21(9):905-8. PubMed ID: 24750260
[TBL] [Abstract][Full Text] [Related]
14. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
Stephenson AJ; Tal R; Sheinfeld J
J Urol; 2006 Nov; 176(5):1996-9; discussion 1999. PubMed ID: 17070234
[TBL] [Abstract][Full Text] [Related]
16. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
[TBL] [Abstract][Full Text] [Related]
17. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
18. Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases.
Comiter CV; Kibel AS; Richie JP; Nucci MR; Renshaw AA
J Urol; 1998 Mar; 159(3):859-63. PubMed ID: 9474169
[TBL] [Abstract][Full Text] [Related]
19. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
Eggener SE; Carver BS; Sharp DS; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2007 Mar; 177(3):937-42; discussion 942-3. PubMed ID: 17296380
[TBL] [Abstract][Full Text] [Related]
20. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer.
Steiner H; Zangerl F; Stöhr B; Granig T; Ho H; Bartsch G; Peschel R
J Urol; 2008 Oct; 180(4):1348-52; discussion 1352-3. PubMed ID: 18707723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
